Clinical Trial Search

Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11

Primary: Treatment Phase 1 (Treatment Cycle 1)- Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 6 — -0.18; -3.20 Episodes

Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale

Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale

Primary: Change From Baseline in Anticholinergic Drug Use — 305.21; 199.77 Doses of Anticholinergic Drugs

Primary: Average Number of Catheterizations Without Leaking Per Day — 2.4; 1.5 Number of Dry Catheterizations per Day

Primary: Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes — 4.18; 4.32; -3.34; -1.10 Episodes

Primary: Willingness to Repeat Procedure — 9.16; 9.34; 9.73; 9.67 units on a scale — p=0.57

Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 37.0 mL — p=<0.001

Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes

Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes

Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants

Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes

Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 57.2; 59.3 mL — p=<0.001

Primary: Change From Study Baseline in the Daily Normalized Daytime Average Number of Urinary Incontinence Episodes in Treatment Cycle 1 — 2.66; 2.97; 3.99; -1.19 urinary…

Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants

Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05

Primary: Change in Number of Urinary Urge Incontinence (UUI) Episodes Per Day After the 12th PTNM Therapy Sessions From Baseline — -2.4 UUI episodes per day — p=<0.0001

Primary: Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6 — -0.45; 16.91; 13.82; 15.32 percentage of point — p=0.0928

Primary: Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24 — 72.09; 113.21 mL — p=<0.001

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109 — 2; 9; 2; 6…

Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016

Primary: Urethral Sphincter Pressure — 50 cmH2O

Primary: Change From Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes — -1.30; -1.30; -1.34 urinary incontinence episodes per day — p=0.9949

Primary: Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment — 2.6; 2.6; 3.5; 2.6 BOLD Signal Change Derived T-Value — p=0.0012

Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722

Primary: Persistent Retention — 29; 21 participants

Primary: Change in Mean Daily Urgency Incontinence Episodes — -2.5; -2.5 number of incontinence episodes/24 hours

Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin

Primary: Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day. — 35.3; 45.7…